Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Shares Sold by Vivo Capital LLC

Vivo Capital LLC trimmed its position in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) by 9.0% during the fourth quarter, Holdings Channel.com reports. The firm owned 3,521,291 shares of the company’s stock after selling 350,000 shares during the period. Vivo Capital LLC owned 0.09% of Bolt Biotherapeutics worth $3,944,000 at the end of the most recent quarter.

Separately, Newtyn Management LLC lifted its stake in shares of Bolt Biotherapeutics by 2.0% during the third quarter. Newtyn Management LLC now owns 1,020,000 shares of the company’s stock valued at $1,061,000 after buying an additional 20,000 shares during the period. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Trading Up 0.8 %

Shares of NASDAQ BOLT traded up $0.01 on Thursday, reaching $1.12. 2,645 shares of the company traded hands, compared to its average volume of 112,086. The stock has a market capitalization of $42.64 million, a PE ratio of -0.61 and a beta of 1.05. Bolt Biotherapeutics, Inc. has a fifty-two week low of $0.84 and a fifty-two week high of $2.03. The company has a current ratio of 5.17, a quick ratio of 5.17 and a debt-to-equity ratio of 0.15. The company has a 50 day moving average of $1.20 and a 200 day moving average of $1.10.

Bolt Biotherapeutics (NASDAQ:BOLT) last issued its earnings results on Thursday, March 21st. The company reported ($0.47) earnings per share for the quarter, hitting the consensus estimate of ($0.47). The business had revenue of $2.09 million for the quarter, compared to analyst estimates of $1.97 million. Bolt Biotherapeutics had a negative return on equity of 51.18% and a negative net margin of 878.58%. On average, equities research analysts forecast that Bolt Biotherapeutics, Inc. will post -1.68 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $8.00 target price on shares of Bolt Biotherapeutics in a research note on Friday, March 22nd.

Bolt Biotherapeutics Profile

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company's lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.